SARS-CoV-2 infection in high-risk children following tixagevimab–cilgavimab (Evusheld) pre-exposure prophylaxis: a single-center observational study
-
Published:2023-08-03
Issue:
Volume:13
Page:
-
ISSN:2234-943X
-
Container-title:Frontiers in Oncology
-
language:
-
Short-container-title:Front. Oncol.
Author:
Hijano Diego R.,Ferrolino Jose A.,Swift Elizabeth G.,Michaels Carolyn A.,Max Anita,Hayden Randall T.,Wolf Joshua,Dallas Ronald H.,Greene William L.,Richardson Julie L.,Hakim Hana,Morton Ted H.,Cross Shane J.
Abstract
From 8 December 2021 to 26 January 2023, tixagevimab–cilgavimab (T-C) was authorized for pre-exposure prophylaxis of COVID-19. During this period, we used a multidisciplinary team to communicate, screen, approach, and administer T-C to eligible patients. Twenty-seven patients were eligible. Of these, 24 (88.9%) received at least one dose of T-C and three patients received two doses. Majority of patients were White, non-Hispanic, and women. Only two patients had COVID-19 prior to receiving T-C. Seventeen (70.8%) had received two or more doses of SARS-CoV-2 vaccine. No serious adverse events were noted. Seven patients developed SARS-CoV-2 infection within 180 days of receiving T-C (median 102 days; range 28–135), and only one patient developed severe COVID-19 requiring intensive mechanical ventilation in the intensive care unit.
Funder
American Lebanese Syrian Associated Charities
Publisher
Frontiers Media SA
Subject
Cancer Research,Oncology
Reference44 articles.
1. Origin, transmission, diagnosis and management of coronavirus disease 2019 (COVID-19);Umakanthan;Postgrad Med J,2020
2. WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 March 2020
3. Post acute (long) COVID-19 quality of life;Umakanthan;Front Public Health,2023
4. Post-acute coronavirus (COVID-19) syndrome;Chippa,2023
5. COVID Data Tracker2022
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Cilgavimab/tixagevimab;Reactions Weekly;2023-10-28